# Phase 1/2 sclerosis trials recruiting: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 1/2 for sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 sclerosis trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932262 | An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 | University Hospital Tuebingen | Phase 1/2 | Not yet recruiting | Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV), Rheumatoid Arthritis (RA), IIM, Multiple Sclerosis, Immune... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932262) |
| October 2, 2026 | NCT07855211 | A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Biogen | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855211) |
| September 17, 2026 | NCT07826689 | A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis | Progentos Therapeutics | Phase 1/2 | Recruiting | Multiple Sclerosis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07826689) |
| September 17, 2026 | NCT07825389 | C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis... | AbelZeta Inc. | Phase 1/2 | Not yet recruiting | Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary... | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825389) |
| August 10, 2026 | NCT07756268 | Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis | Tongji Hospital | Phase 1/2 | Not yet recruiting | Multiple Sclerosis | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756268) |
| June 29, 2026 | NCT07674667 | FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | Trace Neuroscience, Inc. | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674667) |
| June 22, 2026 | NCT07660614 | A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis | Leal Therapeutics, Inc | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660614) |
| June 5, 2026 | NCT07631143 | Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS | University of Saskatchewan | Phase 1/2 | Not yet recruiting | Multiple Sclerosis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631143) |
| May 6, 2026 | NCT07571486 | Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis, Charcot Disease | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571486) |
| March 17, 2026 | NCT07477639 | Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis | Tr1X, Inc. | Phase 1/2 | Recruiting | Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple... | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07477639) |
| February 20, 2026 | NCT07423494 | Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576) | n-Lorem Foundation | Phase 1/2 | Not yet recruiting | Amyotrophic Lateral Sclerosis | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423494) |
| February 17, 2026 | NCT07414212 | Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | Biogipuzkoa Health Research Institute | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414212) |
| February 9, 2026 | NCT07396818 | Kamlanoflast In Amyotrophic Lateral Sclerosis | Inflammasome Therapeutics | Phase 1/2 | Not yet recruiting | ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Motor Neuron Disease... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396818) |
| January 27, 2026 | NCT07369076 | A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369076) |
| December 17, 2025 | NCT07287397 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | Vector Y Therapeutics | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287397) |
| December 17, 2025 | NCT07287202 | Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex... | Sovargen | Phase 1/2 | Recruiting | Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287202) |
| September 17, 2025 | NCT07178431 | MB-CART2019.1 in Refractory Multiple Sclerosis | Miltenyi Biomedicine GmbH | Phase 1/2 | Recruiting | Multiple Sclerosis, CAR T Cell Therapy | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178431) |
| September 11, 2025 | NCT07169175 | A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS | SineuGene Therapeutics Co., Ltd. | Phase 1/2 | Not yet recruiting | Amyotrophic Lateral Sclerosis (ALS) | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169175) |
| July 25, 2025 | NCT07085507 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients | Vidya Therapeutics Inc | Phase 1/2 | Recruiting | Multiple Sclerosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085507) |
| June 12, 2025 | NCT07017946 | Intestinal Microbiome Transplant in ALS | Duke University | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis ALS | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07017946) |
| December 10, 2024 | NCT06726577 | TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06726577) |
| July 22, 2024 | NCT06513546 | A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients | PLL TX AUSTRALIA PTY LTD | Phase 1/2 | Not yet recruiting | Amyotrophic Lateral Sclerosis, ALS | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06513546) |
| April 8, 2024 | NCT06351592 | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06351592) |
| October 3, 2023 | NCT06063850 | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | UniQure Biopharma B.V. | Phase 1/2 | Recruiting | Mesial Temporal Lobe Epilepsy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06063850) |
| September 8, 2022 | NCT05532943 | Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Ever Supreme Bio Technology Co., Ltd. | Phase 1/2 | Recruiting | Multiple Sclerosis | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05532943) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Brigham and Women's Hospital | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| SineuGene Therapeutics Co., Ltd. | 1 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 1 |
| Trace Neuroscience, Inc. | 1 |
| PLL TX AUSTRALIA PTY LTD | 1 |
| University of Saskatchewan | 1 |
| [Biogen](https://specstream.ai/data/clinical-trials/company/biogen) | 1 |
| Duke University | 1 |
| AbelZeta Inc. | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
| Q Therapeutics, Inc. | 1 |
| n-Lorem Foundation | 1 |
| University Hospital Tuebingen | 1 |
| The Hospital for Sick Children | 1 |
| Inflammasome Therapeutics | 1 |
| Talengen Institute of Life Sciences, Shenzhen, P.R. China. | 1 |
| Tongji Hospital | 1 |
| Progentos Therapeutics | 1 |
| Ever Supreme Bio Technology Co., Ltd. | 1 |
| Sovargen | 1 |
| Tr1X, Inc. | 1 |
| Biogipuzkoa Health Research Institute | 1 |
| Leal Therapeutics, Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 13 |
| Australia | 5 |
| Germany | 5 |
| Netherlands | 4 |
| Canada | 3 |
| China | 3 |
| Belgium | 2 |
| Poland | 2 |
| Sweden | 2 |
| Taiwan | 2 |
| United Kingdom | 2 |
| France | 1 |
| Japan | 1 |
| South Korea | 1 |
| Spain | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Pediatric pulmonology practices in the United States](https://specstream.ai/data/businesses/pediatric-pulmonology-practices/united-states)
- [Window washing companies in the United States](https://specstream.ai/data/businesses/window-washing-companies/united-states)
- [Diners in the United States](https://specstream.ai/data/businesses/diners/united-states)
